Sigumir®
Biologically active food supplement SIGUMIR® contains a complex of low molecular weight peptides
with a molecular weight of up to 5000 Da, isolated from the cartilage tissue of young animals - calves
up to 12 months of age or pigs.
SIGUMIR® is available in tablets or capsules with an active ingredient content of 10 mg.
Experimental studies have shown that peptides have a tissue-specific effect on the cells of those tis-
sues from which they are isolated. They improve the trophism of cartilage cells and have a regulatory
effect on its metabolic processes, reducing the risk of various lesions of the joints and spine. This sug-
gests the effectiveness of the use of SIGUMIR® to restore the function of cartilage tissue in inflam-
matory and dystrophic-degenerative diseases of the musculoskeletal system.
Clinical trials of SIGUMIR® were carried out at the Medical Center of the St. Petersburg Institute of
Bioregulation and Gerontology in patients with osteoarthritis of the joints, osteochondrosis of the
spine, and osteoporosis in the period from November 2005 to February 2006.
SIGUMIR® was administered to patients orally 10-15 minutes before meals, 1-3 capsules 2-3 times
a day for 30-45 days, depending on the severity of the pathological process.
The treatment and rehabilitation of patients with degenerative-dystrophic diseases of the joints and
spine, occurring with irreversible, progressive manifestations, is a complex problem that is most ur-
gent in geriatric practice (2, 3).
Drug therapy for degenerative-dystrophic diseases of the joints and spine includes the use of various
drugs of symptomatic and pathogenetic action (1):
- Analgesics and anti-inflammatory drugs (analgin, novocaine blockade, rheopyrin, indomethacin,
brufen);
- Antihistamines (diphenhydramine, pipolfen);
- Drugs that improve peripheral blood circulation (pachikarpin, platifillin);
- Biostimulants (rumalon, aloe, vitreous body, ATP);
- Enzyme medication (lidase, ronidase);
- Anabolic steroids (nerabol, retabolil);
- etc.
CLINICAL CHARACTERISTICS OF PATIENTS
Treatment with SIGUMIR® was carried out in 33 patients with diagnoses of osteoarthritis of the knee
joints (10 people, including 7 men, 3 women), osteochondrosis of the spine (15 people, including 6
men, 9 women), osteoporosis ( 8 women). The patients’ age ranged from 45 to 78 years.
The control group included 31 patients with similar diagnoses, gender, and age. The distribution of
patients by diagnosis, sex, and age is shown in Table 1.
Osteoporotic patients complained of frequent bone fractures arising from minor trauma or even for
no apparent reason.
The duration of the course of the disease ranged from 5 to 20 years. There were progressive dynam-
ics of the development of the pathological process.
In patients of the primary and control groups, the duration of the disease ranged from 5 to 20 years,
and there were progressive dynamics of the development of the pathological process.
All patients had previously received analgesics and anti-inflammatory drugs for a long time, the use
of which caused a short-term therapeutic effect, requiring an increase in the dose of drugs for the
course of treatment and their prolonged use.
Patients in the control group received treatment using conventional means. In addition to conven-
tional means, patients of the primary group were prescribed SIGUMIR® 2-3 capsules 2-3 times a day
before meals for 30-45 days.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.